Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-10-21, Stock:ABBV, The news for the past five days is as follows:
2020-10-14: NEWS1: Better Buy: AbbVie vs. Johnson & Johnson.
2020-10-15: NEWS1: Remdesivir didn't reduce mortality among COVID-19 in WHO study: Report.NEWS2: The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK.
2020-10-16: NEWS1: VENCLEXTA® (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML).NEWS2: Coronavirus update: Global COVID-19 cases top 38.9 million as trial of promising therapy finds it does not stop patients dying.NEWS3: Study finds remdesivir, hydroxychloroquine have 'little' impact on mortality in COVID-19 patients.NEWS4: 5 High-Yield Stocks for 5%-Plus Dividend Payouts.
2020-10-19: NEWS1: AbbVie Submits Anti-Inflammatory Drug Rinvoq for FDA, Europe Approval for Atopic Dermatitis.NEWS2: Analyst Report: AbbVie Inc..NEWS3: AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis.NEWS4: Roche (RHHBY), AbbVie's Leukemia Drug Venclexta Get Full FDA Nod.NEWS5: AbbVie Announces Commencement of Registered Exchange Offers.
2020-10-20: NEWS1: AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know.NEWS2: Were Hedge Funds Right About Crowding AbbVie Inc (ABBV)?.NEWS3: AbbVie (ABBV) Files for Rinvoq in Atopic Dermatitis in US & EU.NEWS4: AbbVie Submits US, EU Rinvoq Applications For Atopic Dermatitis.

Answer: Decrease